Back to Search
MICHAEL MCCLUNG, M.D.
M.D.
Endocrinology, Diabetes & Metabolism Physician
NPI: 1477580207Individual
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
MD10002(OR)
Research & Publications (20)
The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?
PMID 19287893·Salud Publica Mex·2009
6-review
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
PMID 18950736·Bone·2009
2-rct
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
PMID 18539106·Bone·2008
3-trial
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
PMID 17468062·Bone·2007
4-observational
Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.
PMID 16527005·Curr Osteoporos Rep·2006
6-review
Denosumab in postmenopausal women with low bone mineral density.
PMID 16495394·N Engl J Med·2006
3-trial
Do current management strategies and guidelines adequately address fracture risk?
PMID 16403495·Bone·2006
6-review
The relationship between bone mineral density and fracture risk.
PMID 16036103·Curr Osteoporos Rep·2005
6-review
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
PMID 14753731·J Bone Miner Res·2004
3-trial
Parathyroid hormone for the treatment of osteoporosis.
PMID 15572960·Obstet Gynecol Surv·2004
6-review
Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.
PMID 15472179·J Clin Endocrinol Metab·2004
3-trial
Use of highly potent bisphosphonates in the treatment of osteoporosis.
PMID 16036074·Curr Osteoporos Rep·2003
6-review
The menopause and HRT. Prevention and management of osteoporosis.
PMID 12763512·Best Pract Res Clin Endocrinol Metab·2003
6-review
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
PMID 11172164·N Engl J Med·2001
3-trial
Bisphosphonates in osteoporosis: recent clinical experience.
PMID 11249544·Expert Opin Pharmacother·2000
6-review
Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice.
PMID 11033474·Ann Med Interne (Paris)·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5050 NE HOYT ST, SUITE 651
PORTLAND, OR 97213 - Phone
- (503) 215-6586
Quick Facts
- NPI
- 1477580207
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile